Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor.
Leyvraz S, Ketterer N, Perey L, Bauer J, Vuichard P, Grob JP, Schneider P, von Fliedner V, Lejeune F, Bachmann F. Leyvraz S, et al. Among authors: lejeune f. Br J Cancer. 1995 Jul;72(1):178-82. doi: 10.1038/bjc.1995.298. Br J Cancer. 1995. PMID: 7541235 Free PMC article.
Sequential high-dose combination chemotherapy with granulocyte colony-stimulating factor and peripheral blood progenitor cells in patients with solid tumors: intensification limited by nonhematologic toxic effects.
Leyvraz S, Ketterer N, Vuichard P, von Fliedner V, Lejeune F, Schneider P, Grob JP, Bachmann F. Leyvraz S, et al. Among authors: lejeune f. J Natl Cancer Inst. 1993 Dec 1;85(23):1962-4. doi: 10.1093/jnci/85.23.1962. J Natl Cancer Inst. 1993. PMID: 7693957 No abstract available.
Soft tissue sarcoma therapy: prospects for future studies.
Lejeune FJ, Liénard D, Rüegg C, Leyvraz S. Lejeune FJ, et al. Eur J Surg Oncol. 1995 Oct;21(5):474-7. doi: 10.1016/s0748-7983(95)96713-3. Eur J Surg Oncol. 1995. PMID: 7589588 Review. No abstract available.
Regional therapy of melanoma.
Lejeune FJ, Liénard D, Leyvraz S, Mirimanoff RO. Lejeune FJ, et al. Eur J Cancer. 1993;29A(4):606-12. doi: 10.1016/s0959-8049(05)80163-7. Eur J Cancer. 1993. PMID: 8435217 Review.
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F. Marzolini C, et al. Among authors: lejeune f. Cancer Chemother Pharmacol. 1998;42(6):433-40. doi: 10.1007/s002800050842. Cancer Chemother Pharmacol. 1998. PMID: 9788568 Clinical Trial.
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Gander M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F, Liénard D, Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M, D'Incalci M. Gander M, et al. Among authors: lejeune f. Ann Oncol. 1999 Jul;10(7):831-8. doi: 10.1023/a:1008304032421. Ann Oncol. 1999. PMID: 10470431 Free article. Clinical Trial.
Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy.
Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman SL, Bauer J, Leyvraz S, Lejeune F, Stupp R, Rüegg C. Zaman K, et al. Among authors: lejeune f. Int J Cancer. 2006 Feb 1;118(3):755-64. doi: 10.1002/ijc.21408. Int J Cancer. 2006. PMID: 16114015
552 results